Tumor News and Research

RSS

Cholesterol-lowering drugs may reduce inflammation in prostate tumors

Cholesterol-lowering drugs called statins may reduce inflammation in prostate tumors, possibly hindering cancer growth, according to a study led by investigators in the Duke Prostate Center.

26 Apr 2009

New diagnostic technique found for most common bladder tumors

Making tumors inside the bladder fluoresce red under blue light allows physicians to more easily find and remove them, substantially reducing the rate at which these cancers come back, says a Mayo Clinic physician who is presenting results of a large, multicenter international clinical trial.

26 Apr 2009

da Vinci robot-assisted technology when used for urothelial cancer of the kidney proves to be beneficial for patients

Robotic trained surgeons at Fox Chase Cancer Center in Philadelphia presented a new and novel approach to surgically treat urothelial cancer (in the lining of the bladder or kidney) today at the American Urological Association's Annual Meeting.

26 Apr 2009

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).

26 Apr 2009

Study links arm/hand swelling to number of lymph nodes removed during breast cancer surgery

In older breast cancer survivors, the number of lymph nodes removed during surgery and the presence of cancer in the lymph nodes were the two factors most directly linked to the development of lymphedema, swelling of the arm and hand, according to a study from the Medical College of Wisconsin's Center for Patient Care and Outcomes Research in Milwaukee, Wisconsin.

23 Apr 2009

Radiation device in the breast reduces complications for early stage breast cancer patients

A new study shows that the SAVI™ applicator, a small, expandable device inserted inside the breast to deliver partial breast irradiation, carries a low infection risk, a potential complication of such devices.

23 Apr 2009

Diffusion weighted MR accurately identifies gynecologic malignancies

Diffusion weighted MR can accurately identify benign from malignant pelvic lymph nodes in patients with gynecologic malignancy, according to a study performed at Massachusetts General Hospital in Boston, MA.

23 Apr 2009

New drug restricts the growth of neuroblastoma

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a new drug that restricts the growth of neuroblastoma, a childhood brain cancer.

23 Apr 2009

Breakthrough method for sequencing-based methylation profiling

Bioengineers at UC San Diego have developed a breakthrough method for sequencing-based methylation profiling, which could help fuel personalized regenerative medicine and even lead to more efficient and cost-effective methods for studying certain diseases.

23 Apr 2009

DTI allows radiologists to see areas of the brain rarely seen using other imaging modalities

Radiologists are now able to look at parts of the brain using diffusion tensor imaging (DTI) that are rarely visible with any other imaging method, according to a study performed at Beth Israel Deaconess Medical Center in Boston, MA.

23 Apr 2009

Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma

A combination of sorafenib and vitamin K had an effect in vitro on both human pancreas cancer and hepatocellular carcinoma, according to researchers from the Kimmel Cancer Center at Jefferson.

22 Apr 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

Hormone therapy may lower colorectal cancer risk in women

In a large study, a national team of researchers led by Mayo Clinic scientists observed that self-reported use of hormone therapy was associated with a significantly lower colorectal cancer risk.

22 Apr 2009

Lymphocytes promote cancer spread

Researchers at the UC San Diego School of Medicine and the Moores UCSD Cancer Center have new evidence that a type of immune system cell thought to be part of the first line of defense against breast cancer may also help promote its spread.

22 Apr 2009

New applications for proton pump inhibitors

In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.

22 Apr 2009

Engineered antibody gives cancer the recognition it deserves

In concept, the human immune system has the power to destroy cancer cells with great specificity.

22 Apr 2009

Walnuts can reduce breast cancer risk

Walnut consumption may provide the body with essential omega-3 fatty acids, antioxidants and phytosterols that reduce the risk of breast cancer, according to a study presented at the American Association for Cancer Research 100th Annual Meeting 2009.

22 Apr 2009

Retooled chemotherapy agents for drug delivery may increase effectiveness

Researchers may have found a way to combine imaging with chemotherapy in a single agent for the treatment of prostate cancer, according to data presented at the American Association for Cancer Research 100th Annual Meeting 2009

22 Apr 2009

Common gene variant linked to development of prostate cancer

Researchers have described how a common genetic variation may be involved in the development of prostate cancer.

22 Apr 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009